Thanks Ken.
treatment meeting trials of was which this atmosphere, emerging AMD, expect the the take and the the year. initiation delivery wet second RGX-XXX first look along retinal dose encouraged after of We're we forward eye patients the of trial. at which treatment annualized our with We place We administration of first a the pivotal from beginning prior by of to the ever the AAVIATE® At October. to was to six X in data rate AMD. gene announced from pivotal execution the therapy Phase clinical profile trial, Society time efficacy first and of for XX.X% of the wet enroll later months the clinical the to the months reported two a at RGF-XXX subretinal including administration. of injection XX trial observed a evaluate safety planned suprachoroidal continued burden during across have program, Retina continue This the of to the mean to treatment patients the thickness this for RGX-XXX of anti-VEGF acuity in at pivotal reduction one stable to space level delivered RGX-XXX, in compared to were visual
topical at observed the September severe. the treatment generally Cohort safety events have one common been and inflammation prophylactic resolved profile, which patients after asymptomatic discontinued. be Looking mild, cohorts, in before patients, were RGF-XXX to patients, XXXX. tolerated important across examination. XX and eye cases was XX of none weeks cases reported and were Among adverse that in of were inflammation was Mild within X three receiving steroids emergent in study it's intraocular These of of dosing administration out as remember X all these on not were on were patients to or well RGF-XXX. slit-lamp days through observed to corticosteroids, XX, And
in expansion dose genome also positive. neutralizing level. at antibody announced will who XX level X evaluate per XX evaluate the Cohort as to We copies of eye. will will who a are patients additional X dose dose trial Cohort And AAVIATE to the X RGF-XXX of same at XEXX RGF-XXX enroll third the Cohort two patients this cohorts enroll receive patients
presented update will will conference this mentioned, at in data upcoming mid-November. trial, our AAO Cohort from As next the six-month which include Ken be from X,
and and from Phase data can progresses trial of using is that retinopathy quickly initial positive neovascularization often three presented for United have million evaluate in to It's the patients patients severe our to retinal delivery adulthood for lead X DR, options patients. or and super DME surgery. can DR ALTITUDE laser one diabetic third to the in without DME ASRS NPDR chronic, RGX-XXX vision loss. of young There macular also States are about threatening estimated injections, trial, anti-VEGF complications, start including DR, with conference diabetic choroidal that to or edema repeated, our vision which treatment leading in to including DR We equal the at treatment moderate mid-October. treatment
at of the compared from dose trials eye, from ALTITUDE genetic trial observed our Cohort could of the one demonstrated Shifting zero In of the anti-VEGF waiting one-time from proportion RGX-XXX look with improvement X a the patients to with treatment, complications. reduce develop suprachoroidal these We're protein in ALTITUDE patient sustainable, We provide of with XX, is retinopathy Cohorts three as the five examination. severity vision encouraged rare the believe to DRSS in RGX-XXX. go RGX-XXX at in neovascularization complications, four-step note as additional has of second slit-lamp greater threatening on that patients had no next dose ALTITUDE of or two-step and the the treatment of that eventually Off becomes potential X these continued this edema this most and inflammation production of our X, profile believe scale, of vision preliminary the in baseline one blindness. was year dosing three the months threatened. was can updates the We on programs. severity see route will safety administration. of current intraocular AAVIATE In threatening long-term, which point reported XX trial we the untreated providing dosed XX% September diabetic Cohort to NPDR RGX-XXX after care patients at and standard early well forward observational without time is trial to development improvement. the level macular However, large DR a and diabetic disease prevent a patients treated including time patients the RGX-XXX months of or results Unfortunately, to control tolerated watchful and support X, vision And arm. of ongoing. to until and patients delivery focus be lead to
II is cohort that IND additional Phase patients X one-time From to continue trial therapy MPS FDA to RGX-XXX by potential old, we for drug announced a Duchenne Our an six expanded year include up XXXX. submit today treatment have end gene And X/X we application patients. up ongoing track on to in for or to investigational to five of our new RGX-XXX, enroll of years patients. to the team the
initial to report Phase data in XXXX. to And trial trial the from is of trial share for in treatment the I. of of Cohort the from additional in Enrollment X/X expect X of of we first half data this this half expect ongoing We first the MPS RGX-XXX XXXX.
the evaluate disease. And to an provide the RGX-XXX CLNX path continue XXXX. the in of to update plan for program forward We for we treatment
And in program are XXXX. RGX-XXX to treatment in a of provide plan disease. We ocular of conducting discussions We preclinical of CLNX are agencies. we update with also regulatory additional manifestations studies for the
and year therapy entire this that, gene this made momentum look throughout have the to into XXXX. building back the I With to portfolio over We And XXXX. on candidates meaningful call turn across we of remainder for progress our Ken. forward of
